Study of INT-747 as Monotherapy in Patients With PBC

Mise à jour : Il y a 4 ans
Référence : NCT00570765

Femme et Homme

Extrait

The primary hypothesis is that INT 747 will cause a reduction in alkaline phosphatase levels in PBC patients, over a 12 week treatment period, as compared to placebo.


Critère d'inclusion

  • Liver Cirrhosis, Biliary